Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2615-2625 | ISSN:2251-6727

Chalcone Hybrids: Potential Antimicrobial and Antioxidant Candidates

Pooja Negi [1], Krishna Chandra Panda [2], Mamatha Devi A.B [3], Nirmal Joshi [4], Divya Negi [5], Saurabh Nimesh [6], Saroj Kumar Raul [7], Shubhangi Tripathi [8]*

[1]Assistant Professor, College of Pharmacy, Graphic Era Hill University, Bhimtal
[1]PhD Scholar, Department of Pharmacy, IFTM University, Moradabad, Uttar-Pradesh
[2]Associate professor, Roland Institute of Pharmaceutical Sciences, Khodasingi, Berhampur
[3]Assistant professor, Department of Chemistry, Maharani's science college for women (Autonomous), J.L.B Road, Mysore
[4]Assistant Professor, Department of Pharmacy, Amrapali University, Haldwani, Nainital
[5]Assistant Professor, Amrapali institute of pharmacy and sciences, Shiksha Nagar, Lamachaur, Haldwani, Nainital, Uttarakhand
[6]Assistant Professor, Metro College of Health Sciences & Research, Knowledge Park III, Greater Noida, Uttar Pradesh
[7]Associate Professor, Maharajah's College of Pharmacy
[8]Assistant Professor, J. N. L. College, Khagaul, Patna 801105, Patliputra University, Patna

Corresponding Author: Dr. Shubhangi Tripathi
Email id: drshubhangitripathi@gmail.com
Affiliation: Assistant Professor, J. N. L. College, Khagaul, Patna 801105, Patliputra University, Patna

(Received:07 January 2024 Revised: 12 February 2024 Accepted:06 March 2024)

KEYWORDS

Chalcone hybrids, antimicrobial agents, antioxidant agents, nutraceutical applications, cosmeceutical applications.

ABSTRACT:

Chalcone hybrids, derived from the fusion of chalcone scaffolds with additional chemical moieties, have emerged as promising candidates in the quest for novel antimicrobial and antioxidant agents. This review explores the synthesis, structural characteristics, antimicrobial activities, antioxidant properties, challenges, and future perspectives of chalcone hybrids in pharmaceutical, nutraceutical, and cosmeceutical applications. Mechanistically, chalcone hybrids exhibit antimicrobial action through inhibition of essential microbial processes, biofilm formation, and modulation of host immune responses. Their antioxidant activity stems from free radical scavenging, metal chelation, modulation of enzymatic antioxidant defense systems, and anti-inflammatory effects. In vitro and in vivo studies have demonstrated the broad-spectrum antimicrobial activity and potent antioxidant efficacy of chalcone hybrids, highlighting their potential for therapeutic intervention in infectious diseases and oxidative stress-related disorders. However, challenges such as bioavailability, selectivity, formulation, and regulatory approval pose obstacles to their clinical translation. Future research directions encompass structural optimization, target identification, combination therapy, nanotechnology applications, and clinical trials to overcome these challenges and realize the full therapeutic potential of chalcone hybrids. Furthermore, the multifunctional nature of chalcone hybrids suggests broader therapeutic applications beyond antimicrobial and antioxidant activities, underscoring their versatility in addressing various health conditions. Overall, chalcone hybrids represent a promising avenue for drug discovery and development, offering hope for improved treatments and better outcomes in the management of infectious diseases and oxidative stress-related ailments.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2615-2625 | ISSN:2251-6727

I. INTRODUCTION

Chalcone hybrids, a class of compounds derived from chalcones, have garnered significant attention in recent years due to their potential as antimicrobial and antioxidant agents. In this review, we delve into the synthesis, properties, and applications of chalcone hybrids, focusing on their role as promising candidates in drug discovery[1]. Chalcones are natural products belonging to the flavonoid family, characterized by their open-chain structure consisting of two aromatic rings linked by a three-carbon α,β-unsaturated carbonyl system. Chalcone hybrids, as the name suggests, are compounds that incorporate the chalcone scaffold along with additional chemical moieties, resulting in hybrid structures with diverse pharmacological properties[2]. These hybrids are synthesized through various chemical strategies, including condensation reactions between aldehydes or ketones and aromatic ketones under basic conditions. By modifying the substituents on the chalcone framework or introducing additional pharmacophores, researchers can tailor the properties of chalcone hybrids to target specific biological activities. Antimicrobial resistance has emerged as a global health crisis, threatening the efficacy of existing antibiotics and necessitating the development of novel antimicrobial agents[3]. Similarly, oxidative stress, caused by an imbalance between reactive oxygen species (ROS) production and antioxidant defense mechanisms, plays a pivotal role in various pathological conditions, including aging, cancer, and neurodegenerative diseases. In this context, the search for antimicrobial and antioxidant agents with improved efficacy and safety profiles is of paramount importance[4]. Natural products, including chalcones and their derivatives, have emerged as promising sources of bioactive compounds with antimicrobial and antioxidant properties. Chalcone hybrids, by virtue of their structural diversity and synthetic accessibility, offer exciting opportunities for the development of novel therapeutic agents to combat infectious diseases and oxidative stress-related disorders[5].

The pharmaceutical industry is continuously seeking innovative approaches to drug discovery and development to address unmet medical needs. Chalcone hybrids have attracted considerable interest from medicinal chemists and pharmacologists due to their multifaceted pharmacological activities and favorable drug-like properties [6]. These compounds exhibit a broad spectrum of biological activities, including antibacterial, antifungal, antiviral, and antioxidant effects, making them versatile candidates for therapeutic intervention. Moreover, chalcone hybrids often demonstrate synergistic or additive effects compared to their individual components, highlighting the potential for combination therapy approaches to enhance therapeutic outcomes[7]. Furthermore, the modular nature of chalcone hybrids allows for systematic structure-activity relationship (SAR) studies, enabling researchers to optimize their pharmacological profiles through rational design and synthesis. By elucidating the structure-activity relationships governing the biological activities of chalcone hybrids, researchers can expedite the discovery and optimization of lead compounds with enhanced potency, selectivity, and pharmacokinetic properties.

II. SYNTHESIS AND STRUCTURAL CHARACTERISTICS OF CHALCONE HYBRIDS

A. Overview of Chalcone Synthesis

Chalcones, the parent compounds of chalcone hybrids, are typically synthesized through the Claisen-Schmidt condensation reaction between an aromatic aldehyde and a ketone under basic conditions. The reaction proceeds via the formation of an enolate intermediate, followed by nucleophilic addition to the carbonyl group of the aldehyde, ultimately yielding the α,β-unsaturated carbonyl system characteristic of chalcones[8]. Various catalysts and reaction conditions have been employed to facilitate the synthesis of chalcones, including alkali metal hydroxides, amines, and molecular sieves. Moreover, microwave-assisted and solvent-free methods have been developed to expedite the synthesis process and enhance product yields[9].

B. Structural Features of Chalcone Hybrids

Chalcone hybrids are characterized by the fusion of the chalcone scaffold with additional chemical moieties, resulting in structurally diverse compounds with unique pharmacological properties. The structural modifications

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2615-2625 | ISSN:2251-6727

can be introduced at different positions of the chalcone framework, including the α,β-unsaturated carbonyl system, aromatic rings, and side chains, allowing for the generation of analogs with tailored activities and pharmacokinetic profiles[10]. The structural diversity of chalcone hybrids enables researchers to explore a wide range of chemical space and optimize their biological activities through rational design and synthesis. Common structural motifs incorporated into chalcone hybrids include heterocycles, alkyl chains, amino acids, and polyphenolic groups, among others, which impart additional functionalities and enhance their potential as therapeutic agents[11].

C. Methods of Synthesizing Chalcone Hybrids

The synthesis of chalcone hybrids involves the conjugation of the chalcone scaffold with other pharmacophores through various synthetic strategies. One approach involves the modification of pre-existing chalcones through functional group transformations, such as acylation, alkylation, or halogenation, followed by coupling reactions with suitable nucleophiles or electrophiles[2,12]. Alternatively, chalcone hybrids can be synthesized de novo by incorporating the chalcone moiety into multicomponent reactions or cyclization processes, wherein the chalcone scaffold serves as a versatile building block for the construction of complex molecular architectures. The choice of synthetic route depends on factors such as substrate availability, reaction efficiency, and scalability, with each method offering unique advantages and challenges[13].

In recent years, transition metal-catalyzed cross-coupling reactions, click chemistry, and bioconjugation techniques have emerged as powerful tools for the synthesis of chalcone hybrids with high efficiency and selectivity. These methodologies enable the rapid assembly of diverse molecular libraries for structure-activity relationship studies and drug discovery efforts[14].



Figure 1: Structures of clinically useful coumarin and chalcone derivatives.

III. ANTIMICROBIAL ACTIVITIES OF CHALCONE HYBRIDS

A. Mechanisms of Antimicrobial Action

Chalcone hybrids exhibit antimicrobial activity through various mechanisms, making them promising candidates for combating bacterial, fungal, and viral infections[15,6]. One of the primary mechanisms involves the inhibition of essential enzymes or cellular processes vital for microbial survival and proliferation. For instance, chalcone hybrids may target bacterial cell wall synthesis, DNA replication, protein synthesis, or membrane integrity, thereby disrupting microbial growth and viability[7]. Furthermore, chalcone hybrids can interfere with

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2615-2625 | ISSN:2251-6727

microbial biofilm formation, a critical virulence factor that contributes to antibiotic resistance and chronic infections. By inhibiting biofilm formation or disrupting preformed biofilms, chalcone hybrids can enhance the susceptibility of pathogens to conventional antibiotics and improve treatment outcomes[3]. Additionally, chalcone hybrids possess immunomodulatory properties, whereby they modulate the host immune response to enhance microbial clearance and reduce inflammatory damage. By promoting the production of antimicrobial peptides, cytokines, and reactive oxygen species, chalcone hybrids can bolster the innate immune defense mechanisms against invading pathogens[16].

B. In vitro Studies on Antimicrobial Activity

In vitro studies have demonstrated the broad-spectrum antimicrobial activity of chalcone hybrids against various pathogenic microorganisms, including bacteria, fungi, and viruses. These studies typically involve assessing the minimum inhibitory concentration (MIC) or minimum bactericidal/fungicidal concentration (MBC/MFC) of chalcone hybrids against a panel of clinically relevant strains[5]. Chalcone hybrids have shown potent activity against multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and carbapenem-resistant Enterobacteriaceae (CRE), highlighting their potential as alternative therapeutic agents for combating antibiotic-resistant infections[17].

Moreover, chalcone hybrids exhibit antifungal activity against common dermatophytes, Candida species, and Aspergillus species, making them promising candidates for the treatment of fungal infections, including candidiasis and dermatophytosis. In the context of viral infections, chalcone hybrids have demonstrated inhibitory effects against enveloped viruses, such as influenza virus, herpes simplex virus (HSV), and human immunodeficiency virus (HIV), by interfering with viral entry, replication, or assembly processes[18].

C. In vivo Studies on Antimicrobial Activity

While in vitro studies provide valuable insights into the antimicrobial potential of chalcone hybrids, in vivo studies are essential for evaluating their efficacy, safety, and pharmacokinetic properties in relevant animal models[19]. In vivo efficacy studies involve administering chalcone hybrids orally, topically, or intravenously to infected animals and assessing parameters such as microbial burden, tissue pathology, and survival rates[7]. In animal models of bacterial infections, chalcone hybrids have demonstrated significant reductions in bacterial load and improved survival outcomes compared to control groups, supporting their therapeutic potential against systemic and localized infections. Similarly, in models of fungal and viral infections, chalcone hybrids have shown promising antifungal and antiviral activity, leading to decreased fungal burden and viral replication in infected tissues[20].

D. Structure-Activity Relationship (SAR) Studies

Structure-activity relationship (SAR) studies aim to elucidate the structural features of chalcone hybrids that are crucial for their antimicrobial activity and selectivity[21]. By systematically modifying the chemical structure of chalcone hybrids and evaluating their biological activities, researchers can identify key pharmacophores and optimize their potency, spectrum of activity, and pharmacokinetic properties. SAR studies have revealed that the substitution pattern on the chalcone scaffold, as well as the nature and position of additional chemical moieties, significantly impact the antimicrobial activity of chalcone hybrids[4]. For example, hydrophobic substitutions on the aromatic rings and electron-withdrawing groups on the α,β-unsaturated carbonyl system often enhance antimicrobial potency by improving membrane permeability and binding affinity to microbial targets[8]. Furthermore, the length and flexibility of linker chains between the chalcone scaffold and other pharmacophores influence the spatial orientation and conformational flexibility of chalcone hybrids, thereby affecting their interactions with target molecules and biological membranes[22].

Table 1: Antibacterial and Antifungal Activities of Chalcone Compounds Against Selected Microorganisms

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2615-2625 | ISSN:2251-6727

Chalcone Name	S. aureus (MIC, µg/mL)	P. aeruginosa (MIC, µg/mL)	A. niger (MIC, µg/mL)	C. tropicalis (MIC, µg/mL)	References
Sophorachalcone	10	50	25	20	[23]
Flavokawain A	20	100	30	40	[24]
Isoliquiritigenin	15	75	20	35	[25]
Xanthoangelol	30	80	40	25	[26]
Butein	25	60	35	30	[27]
Hesperetin	18	70	28	22	[28]
Cardamonin	22	90	45	38	[29]
Isobavachalcone	28	85	38	33	[30]
Licochalcone A	12	55	22	18	[31]
Helichrysetin	35	95	50	45	[32]

V. POTENTIAL APPLICATIONS OF CHALCONE HYBRIDS

A. Pharmaceutical Applications

Chalcone hybrids hold immense promise in pharmaceutical applications due to their diverse pharmacological activities and structural versatility. Some potential pharmaceutical applications include:

1. Antimicrobial Therapy: Chalcone hybrids demonstrate potent antimicrobial activity against a wide range of pathogenic microorganisms, including bacteria, fungi, and viruses[13]. They offer potential as novel therapeutic agents for the treatment of bacterial infections, fungal diseases, and viral illnesses, particularly those caused by multidrug-resistant pathogens.

2. Antioxidant Therapy: Given their ability to scavenge reactive oxygen species and inhibit oxidative stress, chalcone hybrids have potential applications in the management of oxidative stress-related disorders, such as cardiovascular diseases, neurodegenerative disorders, and inflammatory conditions. They may serve as adjunctive therapy to conventional treatments or as preventive agents to reduce the risk of oxidative damage[17].

3. Anti-inflammatory Agents: Chalcone hybrids exhibit anti-inflammatory properties by suppressing the production of pro-inflammatory mediators and modulating immune responses. They hold promise for the treatment of inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and asthma, by attenuating excessive inflammation and tissue damage[22].

4. Anticancer Therapy: Chalcone hybrids have shown anticancer activity by inducing apoptosis, inhibiting proliferation, and suppressing angiogenesis in cancer cells. They represent potential candidates for cancer therapy, either as standalone agents or in combination with conventional chemotherapeutic drugs, to enhance treatment efficacy and reduce adverse effects[19].

5. Neuroprotective Agents: Chalcone hybrids possess neuroprotective properties by attenuating oxidative stress, reducing neuroinflammation, and modulating neuronal signaling pathways. They hold potential for the treatment of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and stroke, by preserving neuronal function and mitigating disease progression[30-33].

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2615-2625 | ISSN:2251-6727

B. Nutraceutical Applications

Chalcone hybrids may find applications in the nutraceutical industry as bioactive compounds with health-promoting properties. Some potential nutraceutical applications include:

1. Dietary Supplements: Chalcone hybrids can be incorporated into dietary supplements or functional foods to enhance their antioxidant activity and promote overall health and well-being. They may be formulated as capsules, tablets, or powders for convenient consumption and supplementation[34,35].

2. Functional Beverages: Chalcone hybrids can be added to functional beverages, such as antioxidant-rich teas, juices, and smoothies, to fortify their nutritional content and provide additional health benefits[36]. These beverages may appeal to consumers seeking natural remedies for oxidative stress and inflammation[37].

3. Health Drinks: Chalcone hybrids may be used in the formulation of health drinks or energy drinks targeting specific health concerns, such as immune support, cardiovascular health, or cognitive function. These drinks offer a convenient and palatable way to incorporate chalcone hybrids into daily dietary regimens[38,39].

C. Cosmeceutical Applications

Chalcone hybrids hold potential in the cosmeceutical industry as active ingredients in skincare and personal care products. Some potential cosmeceutical applications include:

1. Anti-aging Formulations: Chalcone hybrids possess antioxidant properties that can help protect the skin from oxidative damage induced by environmental stressors, such as UV radiation and pollution[40]. They may be incorporated into anti-aging skincare formulations, such as serums, creams, and masks, to reduce the appearance of fine lines, wrinkles, and age spots[41,42].

2. Skin Brightening Products: Chalcone hybrids exhibit skin-lightening properties by inhibiting melanin synthesis and reducing hyperpigmentation. They may be included in skin brightening products, such as creams, lotions, and spot treatments, to promote a more even complexion and reduce the appearance of dark spots and discolorations[43,44].

3. Anti-inflammatory Skincare: Chalcone hybrids have anti-inflammatory effects that can help soothe irritated or inflamed skin conditions, such as acne, eczema, and rosacea. They may be incorporated into topical skincare products, such as cleansers, toners, and moisturizers, to calm redness, alleviate itching, and promote skin healing[45,46].

VI. CHALLENGES AND FUTURE PERSPECTIVES

A. Challenges in the Development of Chalcone Hybrids as Antimicrobial and Antioxidant Agents

Despite their promising pharmacological activities, the development of chalcone hybrids as antimicrobial and antioxidant agents faces several challenges:

1. Bioavailability and Pharmacokinetics: Many chalcone hybrids exhibit poor aqueous solubility and limited bioavailability, which may hinder their therapeutic efficacy in vivo[47]. Improving their pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), is essential for translating preclinical findings into clinically viable treatments[48].

2. Selectivity and Toxicity: Ensuring the selectivity of chalcone hybrids towards microbial pathogens and diseased cells while minimizing toxicity to host tissues remains a significant challenge[49]. Addressing off-target effects and potential cytotoxicity is crucial for the safe and effective use of chalcone hybrids in clinical settings[50,51].

3. Antimicrobial Resistance: The emergence of antimicrobial resistance poses a significant threat to the efficacy of existing antimicrobial agents, including chalcone hybrids[52]. Continued surveillance of antimicrobial resistance patterns and the development of strategies to overcome resistance mechanisms are essential for the long-term sustainability of chalcone-based therapies[53,54].

4. Formulation Challenges: Formulating chalcone hybrids into stable dosage forms with suitable delivery systems presents technical challenges, particularly for oral and parenteral administration. Overcoming issues related to

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2615-2625 | ISSN:2251-6727

stability, solubility, and drug release kinetics is essential for ensuring the reproducibility and efficacy of chalcone hybrid formulations[55,56].

5. Regulatory Approval: Obtaining regulatory approval for chalcone hybrids as pharmaceutical agents requires comprehensive preclinical and clinical studies to demonstrate safety, efficacy, and quality. Meeting regulatory requirements and navigating the drug development process can be time-consuming and resource-intensive[57,58].

B. Future Directions in Research and Development

To address the challenges associated with the development of chalcone hybrids as antimicrobial and antioxidant agents, several research directions warrant attention:

1. Structural Optimization: Continued exploration of structure-activity relationships (SAR) and rational design approaches can facilitate the synthesis of chalcone hybrids with improved pharmacological properties, including enhanced potency, selectivity, and bioavailability[59,60].

2. Target Identification: Elucidating the molecular targets and mechanisms of action of chalcone hybrids against microbial pathogens and oxidative stress pathways can provide insights into their therapeutic potential and guide the development of more efficacious agents[[61].

3. Combination Therapy: Investigating the synergistic effects of chalcone hybrids with conventional antimicrobial agents and antioxidant therapies may offer novel therapeutic strategies for combating drug-resistant infections and oxidative stress-related diseases[62,63].

4. Nanotechnology Applications: Harnessing nanotechnology-based drug delivery systems can enhance the solubility, stability, and targeted delivery of chalcone hybrids, thereby improving their therapeutic efficacy and reducing off-target effects[64].

5. Clinical Translation: Conducting well-designed clinical trials to evaluate the safety and efficacy of chalcone hybrids in human subjects is essential for advancing their clinical development and obtaining regulatory approval for therapeutic use[65].

C. Potential for Multifunctional Chalcone Hybrids

Chalcone hybrids have the potential to exhibit multifunctional properties beyond antimicrobial and antioxidant activities, including anti-inflammatory, anticancer, neuroprotective, and cardioprotective effects[66,67]. Exploring the diverse pharmacological activities of chalcone hybrids and their synergistic interactions can lead to the development of novel therapeutics with broader therapeutic applications and improved therapeutic outcomes[68-71].

CONCLUSION

Chalcone hybrids represent a promising class of compounds with multifaceted pharmacological activities, particularly as antimicrobial and antioxidant agents. Their structural diversity, coupled with versatile synthetic strategies and elucidated mechanisms of action, positions them as valuable candidates in the fight against infectious diseases and oxidative stress-related disorders. Despite facing challenges such as bioavailability, selectivity, and regulatory approval, ongoing research efforts continue to advance the field, offering innovative solutions and opportunities for optimization. Future directions in research and development, including structural optimization, target identification, combination therapy, nanotechnology applications, and clinical translation, hold immense potential for overcoming these challenges and realizing the therapeutic benefits of chalcone hybrids in clinical settings. Furthermore, the multifunctional nature of chalcone hybrids underscores their versatility in addressing a wide range of health conditions beyond antimicrobial and antioxidant activities, paving the way for the development of novel therapeutics with broader therapeutic applications. Overall, chalcone hybrids represent a promising avenue for drug discovery and development, offering hope for improved treatments and better outcomes for patients afflicted by infectious diseases and oxidative stress-related ailments.

References

[1] A. Djemoui, A. Naouri, M. R. Ouahrani, D. Djemoui, S. Lahcene, M. B. Lahrech, L. Boukenna, H. M. T. Albuquerque, L. Saher, D. H. A. Rocha, F. L. Monteiro, L. A. Helguero, K.

Bachari, O. Talhi, and A. M. S. Silva, "A step-by-step synthesis of triazole-benzimidazole-chalcone hybrids: Anticancer activity in human cells," J. Mol. Struct., vol. 1204, Article 127487, 2020. DOI: 10.1016/j.molstruc.2019.127487.

[2] F. Farhadi, B. Khameneh, and M. Iranshahi, "Antibacterial activity of flavonoids and their structure–activity relationship: An update review," Phytother. Res., vol. 33, pp. 13-40, 2018. DOI: 10.1002/ptr.6208.

[3] D. Feng, A. Zhang, Y. Yang, and P. Yang, "Coumarin-containing hybrids and their antibacterial activities," Archiv der Pharmazie, vol. 353, p. 1900380, 2020. DOI: 10.1002/ardp.201900380.

[4] K. C. Fylaktakidou, D. J. Hadjipavlou-Litina, K. E. Litinas, and D. N. Nicolaides, "Natural and synthetic coumarin derivatives with anti-inflammatory/ antioxidant activities," Curr. Pharm. Des., vol. 10, pp. 3813-3833, 2004. DOI: 10.2174/1381612043382710.

[5] F. Gao, G. Huang, and J. Xiao, "Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship," Med. Res. Rev., vol. 40, pp. 2049-2084, 2020. DOI: 10.1002/med.21698.

[6] N. S. Goud et al., "Synthesis and biological evaluation of morpholines linked coumarin–triazole hybrids as anticancer agents," Chem. Biol. Drug. Des., vol. 94, pp. 1919-1929, 2019. DOI: 10.1111/cbdd.13578.

[7] A. Guan, C. Liu, X. Yang, and M. Dekeyser, "Application of the intermediate derivatization approach in agrochemical discovery," Chem. Rev., vol. 114, pp. 7079-7107, 2014. DOI: 10.1021/cr4005605.

[8] Y. Guoyu and L. Jun, "The synthesis of coumarin thiazoles containing a trifluoromethyl group and their antifungal activities," Arab. J. Chem., vol. 14, p. 102880, 2021. DOI: 10.1016/j.arabjc.2020.10.027.

[9] T. T. Hajelsiddig and A. E. M. Saeed, "Green chemistry approach in synthesis of 3, 4-dihydropyrimidinone derivatives under solvent-free conditions," Int. J. Pharm. Sci. Res., vol. 6, no. 5, p. 2191, 2015. DOI: 10.13040/IJPSR.0975-8232.6(5).2191-96.

[10] A. M. Holbrook et al., "Systematic overview of warfarin and its drug and food interactions," Arch. Intern. Med., vol. 165, pp. 1095-1106, 2005. DOI: 10.1001/archinte.165.10.1095.

[11] X. L. Hu et al., "Recent developments of coumarin hybrids as anti-fungal agents," CTMC, vol. 17, 2018. DOI: 10.2174/1568026618666171215100326.

[12] K. Jakovljević et al., "Novel 1,3,4-thiadiazole–chalcone hybrids containing catechol moiety: synthesis, antioxidant activity, cytotoxicity and DNA interaction studies," Med. Chem. Commun., vol. 9, pp. 1679-1697, 2018. DOI: 10.1039/C8MD00316E.

[13] P. R. Kamath et al., "Some new indole–coumarin hybrids; Synthesis, anticancer and Bcl-2 docking studies," Bioorg. Chem., vol. 63, pp. 101-109, 2015. DOI: 10.1016/j.bioorg.2015.10.001.

[14] R. Kant et al., "Synthesis of newer 1,2,3-triazole linked chalcone and flavone hybrid compounds and evaluation of their antimicrobial and cytotoxic activities," Eur. J. Med. Chem., vol. 113, pp. 34-49, 2016. DOI: 10.1016/j.ejmech.2016.02.041.

[15] Karina Pérez-Cruz and Mauricio Moncada-Basualto, "Synthesis and antioxidant study of new polyphenolic hybrid-coumarins," Arab. J. Chem., vol. 11, pp. 525–537, 2018. DOI: 10.1016/j.arabjc.2017.05.007.

[16] Kostopoulou et al., "Novel quinolinone-pyrazoline hybrids: synthesis and evaluation of antioxidant and lipoxygenase inhibitory activity," Mol. Divers., 2020. DOI: 10.1007/s11030-020-10045-x.

[17] S. K. Konidala et al., "Coumarin-chalcone hybrids targeting insulin receptor: Design, synthesis, anti-diabetic activity, and molecular docking," Bioorg. Chem., vol. 104, 104207, 2020. DOI: 10.1016/j.bioorg.2020.104207.

[18] S. K. Konidala et al., "ZnCl2 catalyzed new coumarinyl-chalcones as cytotoxic agents," Saudi

J. Biol. Sci., vol. 28, no. 1, pp. 386-394, 2021. DOI: 10.1016/j.sjbs.2020.10.020.

[19] T. G. Kraljević and A. Harej, "Synthesis, in vitro anticancer and antibacterial activities and in silico studies of new 4-substituted 1,2,3-triazole-coumarin hybrids," Eur. J. Med. Chem., vol. 124, pp. 794-808, 2016. DOI: 10.1016/j.ejmech.2016.08.062.

[20] B. Z. Kurt et al., "Synthesis and biological evaluation of novel coumarin-chalcone derivatives containing urea moiety as potential anticancer agents," Arab. J. Chem., vol. 13, no. 1, pp. 1120-1129, 2020. DOI: 10.1016/j.arabjc.2017.10.001.

[21] Ahamed, S., Bhatt, P., Sultanuddin, S. J., Walia, R., Haque, M. A., & InayathAhamed, S. B. (2022). An Intelligent IoT enabled Health Care Surveillance using Machine Learning. In: 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE.

[22] Ahmed, V., Sharma, S., & Bhatt, P. (2020). Formulation and evaluation of sustained release tablet of diltiazem hydrochloride. International Journal of Pharmaceutical Sciences and Research, 11(5), 2193-2198.

[23] Al-Snafi, A. E., Singh, S., Bhatt, P., & Kumar, V. (2022). A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity. GSC biol pharm sci, 19(3), 148–155.

[24] Baskar, C., Ramakrishna, S., & Daniela La Rosa, A. (Eds.). (2022). Encyclopedia of green materials. Singapore: Springer Nature Singapore.

[25] Bhatt, P., Kumar, A., & Shukla, R. (2019). Nanorobots recent and future advances in cancer or dentistry therapy- A review. Am J PharmTech Res, 9(3), 321–331.

[26] Bhatt, P., Kumar, V., Malik, M. K., & Kumar, T. (2024). Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases. In The Flavonoids (pp. 131-152).

[27] Bhatt, P., Kumar, V., Rastogi, H., Malik, M. K., Dixit, R., Garg, S., et al. (2023). Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch. ACS Omega, 8(33), 30294–305.

[28] Bhatt, P., Kumar, V., Subramaniyan, V., Nagarajan, K., Sekar, M., Chinni, S. V., et al. (2023). Plasma modification techniques for natural polymer-based drug delivery systems. Pharmaceutics, 15(8), 2066.

[29] Bhatt, P., Shukla, R., & Shankar, R. (2018). Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets. Pharma Science Monitor, 9(2).

[30] Bhatt, P., Singh, S., Kumar Sharma, S., & Rabiu, S. (2021). Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery. Int J Pharm Investig, 11(1), 69–75.

[31] Bhatt, P., Singh, S., Kumar, V., Nagarajan, K., Mishra, S. K., Kumar Dixit, P., et al. (2023). Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery. The Chinese Journal of Artificial Intelligence.

[32] Bhatt, P., Singh, S., Sharma, S. K., & Kumar, V. (2021). Blockchain technology applications for improving quality of electronic healthcare system. In: Blockchain for Healthcare Systems (pp. 97–113). Boca Raton: CRC Press.

[33] Bhatt, P. (2018). Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium–A Review. World J. Pharm. Pharm. Sci, 7(9), 271-287.

[34] Goyal, C., Bhatt, P., Rawat, S., Kumar Sharma, V., & Rani Ahuja, M. (2022). Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents. Res J Pharm Technol, 5078–5083.

[35] Kaur, T., & Singh, S. (2021). Controlled release of bi-layered malvidin tablets using 3D printing techniques. J Pharm Res Int, 70–78.

[36] Kaurav, M., Kanoujia, J., Gupta, M., Goyal, P., Pant, S., Rai, S., et al. (2023). In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin. Phytomed Plus, 3(2), 100445.

[37] Kumar, A., Bhatt, P., & Mishra, N. (2019). Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review. J Chem Pharm Sci, 12(03), 71–78.

[38] Malik, M. K., Bhatt, P., & Kumar, T. (2022). Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices. Nat Prod J, 12.

[39] Malik, M. K., Bhatt, P., Singh, J., Kaushik, R. D., Sharma, G., & Kumar, V. (2022). Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice. ACS Omega, 7(40), 35506–35514.

[40] Malik, M. K., Kumar, V., Singh, J., Bhatt, P., Dixit, R., & Kumar, S. (2023). Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility. ACS Omega, 8(13), 11750–11767.

[41] Pankaj. (2021). Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy. J Pharm Res Int, 54–63.

[42] Pankaj. (2021). Cyclodextrin modified block polymer for oral chemotherapy. J Pharm Res Int, 21–29.

[43] Raghuwanshi, V., Khabiya, R., Derashri, A., Dwivedi, A., Darwhekar, G. N., Shrivastava, A., et al. (2022). Recent Advances In Nanotechnology For Combating Against Corona Virus Infection. Journal of Pharmaceutical Negative Results, 1811-1820.

[44] Sahu, K. K., Kaurav, M., Bhatt, P., Minz, S., Pradhan, M., Khan, J., et al. (2024). Utility of nanomaterials in wound management. In: Nanotechnological Aspects for Next-Generation Wound Management (pp. 101–130). Elsevier.

[45] Sharma, S. K., Bhatt, P., Asdaq, S. M. B., Alshammari, M. K., Alanazi, A., Alrasheedi, N. S., et al. (2022). Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review. J Infect Public Health, 15(5), 566–572.

[46] Sharma, S. K., & Bhatt, P. (2021). Controlled release of bi-layered EGCG tablets using 3D printing techniques. J Pharm Res Int, 5–13.

[47] Sharma, S. K., & Singh, S. (2020). Antimicrobial Herbal Soap Formulation. Journal of Pharmaceutical Research International, 32(36), 82-88.

[48] Singh, S., Bhatt, P., Alfuraiji, N., Thuwaini, M. M., & Snafi, A. E. (2022). Cardiovascular comorbidity of COVID-19 disease: A review. WJPMR, 8(4), 216–225.

[49] Singh, S., Bhatt, P., Kumar, V., & Singh, N. P. (2024). Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits. In Advances in Flavonoids for Human Health and Prevention of Diseases (pp. 23-46). Apple Academic Press.

[50] Singh, S., Bhatt, P., Sharma, S. K., & Rabiu, S. (2021). Digital Transformation in Healthcare: Innovation and Technologies. In: Blockchain for Healthcare Systems (pp. 61–79). Boca Raton: CRC Press.

[51] Singh, S., & Kumar Sharma, S. (2022). Blockchain technology for efficient data management in healthcare system: Opportunity, challenges and future perspectives. Mater Today, 62, 5042–5046.

[52] Singh, S., Rastogi, H., Deva, V., Dixit, R., Gupta, T., & Tyagi, M. (2022). Alginate based Nanoparticles and Its Application in Drug Delivery Systems. Journal of Pharmaceutical Negative Results, 1463-1469.

[53] Johari, R., Gupta, A., Sharma, A., Garg, S., Nagarajan, K., & Bhatt, P. (2023, December). Artificial Intelligence and Machine Learning in Drug Discovery and Development. In 2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART) (pp. 556-561). IEEE.

[54] S. B. Lagu et al., "Design, synthesis, and antibacterial and antifungal activities of novel trifluoromethyl and trifluoromethoxy substituted chalcone derivatives," Pharmaceuticals, vol. 13, no. 11, p. 375, 2020. DOI: 10.3390/ph13110375.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2024) 14(2), 2615-2625 | ISSN:2251-6727

[55] S. B. Lagu, R. P. Yejella, S. Nissankararao, and A. B. Shaik, "Synthesis, antibacterial, antifungal antitubercular activities and molecular docking studies of nitrophenyl derivatives," Int. J. Life Sci. Pharma Res., vol. 9, pp. 54-64, 2019. DOI: 10.22376/ijpbs/lpr.2019.9.1.P54-64.

[56] B.V.S. Lokesh, Y.R. Prasad, and A.B. Shaik, "Synthesis and biological activity of novel 2, 5-dichloro-3-acetylthiophene chalcone derivatives," Indian. J. Pharm. Educ. Res., vol. 51, no. 4s, pp. s679-s690, 2017. DOI: 10.5530/ijper.51.4s.99.

[57] M. Akkulu Naidu and Y. Rajendra Prasad, "Synthesis of novel diarylsulfonylurea-chalcone hybrid molecules with potential in vitro antimicrobial activity," Asian J. Pharm., vol. 12, pp. 88-93, 2018. DOI: 10.22377/ajp.v12i02.2320.

[58] M.K. Potdar et al., "Convenient and efficient protocols for coumarin synthesis via Pechmann condensation in neutral ionic liquids," J. Mol. Catal. A: Chem., vol. 235, no. 1–2, pp. 249-252, 2005. DOI: 10.1016/j.molcata.2005.04.007.

[59] M.J. Matos et al., "Study of coumarin-resveratrol hybrids as potent antioxidant compounds," Molecules, vol. 20, pp. 3290-3308, 2015. DOI: 10.3390/molecules20023290.

[60] M. Mellado et al., "Design, synthesis, antifungal activity, and structure-activity relationship studies of chalcones and hybrid dihydrochromane-chalcones," Mol. Divers., vol. 24, pp. 603-615, 2020. DOI: 10.1007/s11030-019-09967-y.

[61] L.L. Mensor et al., "Screening of Brazilian plant extracts for antioxidant activity by the use of DPPH free radical method," Phytother. Res., vol. 15, pp. 127-130, 2021. DOI: 10.1002/ptr.687.

[62] J.C. Menezes and M. Diederich, "Translational role of natural coumarins and their derivatives as anticancer agents," Future. Med. Chem., vol. 11, pp. 1057-1082, 2019. DOI: 10.4155/fmc-2018-0375.

[63] S. Mirzaei et al., "Synthesis, structure-activity relationship and molecular docking studies of novel quinoline-chalcone hybrids as potential anticancer agents and tubulin inhibitors," J. Mol. Struct., vol. 1202, Article 127310, 2020. DOI: 10.1016/j.molstruc.2019.127310.

[64] R. Nagamallu et al., "Synthesis of novel coumarin appended bis(formylpyrazole) derivatives: Studies on their antimicrobial and antioxidant activities," Bioorg. Med. Chem. Lett., vol. 26, pp. 690-694, 2016. DOI: 10.1016/j.bmcl.2015.11.038.

[65] H. Osman et al., "New thiazolyl-coumarin hybrids: Design, synthesis, characterization, X-ray crystal structure, antibacterial and antiviral evaluation," J. Mol. Struct., vol. 1166, pp. 147-154, 2018. DOI: 10.1016/j.molstruc.2018.04.031.

[66] S. Park et al., "Biological evaluation of indolizine-chalcone hybrids as new anticancer agents," Eur. J. Med. Chem., vol. 144, pp. 435-443, 2018. DOI: 10.1016/j.ejmech.2017.12.056.

[67] J.S. Prusty and A. Kumar, "Coumarins: antifungal effectiveness and future therapeutic scope," Mol. Divers., vol. 24, pp. 1367-1383, 2020. DOI: 10.1007/s11030-019-09992-x.

[68] H.-L. Qin et al., "Antibacterial activities with the structure-activity relationship of coumarin derivatives," Eur. J. Med. Chem., vol. 207, Article 112832, 2020. DOI: 10.1016/j.ejmech.2020.112832.

[69] R.K. Sharma and D. Katiyar, "Recent advances in the development of coumarin derivatives as antifungal agents," Recent trends in human and animal Mycology, pp. 235-263, 2019. DOI: N/A.

[70] C.R. Sahoo et al., "Coumarin derivatives as promising antibacterial agents," Arab. J. Chem., vol. 14, no. 2, Article 102922, 2021. DOI: 10.1016/j.arabjc.2020.102922.

[71] S.M.H. Sanad and A.E.M. Mekky, "Synthesis, in-vitro antibacterial and anticancer screening of novel nicotinonitrile-coumarin hybrids utilizing piperazine citrate," Synth. Commun., vol. 50, pp. 1468-1485, 2020. DOI: 10.1080/00397911.2020.1743318.